Denver ACS: 97 positions for the career fair, 1 position for the Virtual Career Fair.
MERCK: Holy goodness, Merck and Co. 104 (56%) new positions posted, fewer than 20 of which were scientifically connected. I've always known you've wanted to be a black belt manager in Ireland or a manager of social media. (I am not kidding.)
Folks weighing in: Momentive, in heavy with 47 positions (26%). Want to be a Global Operations Black Belt? Shimadzu, looking for field reps at 15 positions (8%). Allergan with 7 positions (4%).
Cambridge, MA +: Metabolix is looking for a M.S./Ph.D. synthetic chemist with 7-10 years of experience; looks like pilot-scale and technology transfer will be key to this position. Nice-ish salary at 82-110k? Lots of travel, looks like.
Sacramento, CA: AMPAC Fine Chemical is looking for a B.S./M.S./Ph.D. synthetic chemist with a desire to work in a plant setting. Sounds like fun.
Emeryville, CA: Amyris is setting up an walk-up analytical facility; they're looking for a chemist to run/maintain it.
Philadelphia, PA: A radiopharmaceutical lab is looking for a postdoc at the University of Pennsylvania. Doubtless, this is one of those niche fields that will have steady employment for the foreseeable future.
New York, NY: A translation medicine lab is looking for a B.S./M.S. synthetic chemist to be a lab manager.
Parlez vous frances, le Merck? (I notice at least 3 more Francophone ads, to compliment the German ad from last week)
ReplyDeleteMERRRCCCKKKKK!!!!!
ReplyDeleteContinual Merck spam. When shall we hear a justification for this disrespect of ACS Careers clients from an official of ACS Careers? What's that? The acoustic signature of crickets?
ReplyDeleteWhat I find most appalling about the Merck ads is that they just announced that they will be cutting 13,000 jobs a week ago. How can they still be hiring 100+ positions with those cuts looming? Obvious case of the left hand not knowing what the right is doing.
ReplyDeleteIf you page through these ads, there's a lot of manufacturing and sales positions. I assume that the sales positions are not slated for big cuts (why cut something that's (presumably) going to bring in money?) and that R&D will take the brunt. Or not. Who knows? The science/non-science ratio is definitely 1:7 or so, though.
ReplyDelete